![]() |
SRI International To Advance Clinical Development Of TAS-108, A Late-Stage Breast Can
SRI International, an independent nonprofit research and development organization, announced that it has assumed responsibility for further clinical development of the TAS-108 breast cancer program, in cooperation with Taiho Pharmaceuticals Co., Ltd., a leading Japanese pharmaceutical company...
More... |
| All times are GMT -7. The time now is 09:06 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021